Drug Neurology

Sympazan

Payments companies reported to CMS as associated with Sympazan. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$141Kassociated payments (2023-2025)
412clinicians with associated payments
1company reporting

By year

2023 $7,917
2024 $86K
2025 $47K

Payments reported as associated with Sympazan, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology With Special Qualifications In Child Neurology $59K
Neurology (Psychiatry & Neurology) $27K
Epilepsy $14K
Family $5,793
Pediatrics (Nurse Practitioner) $4,920
Family Medicine $3,514

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Sympazan

These are the largest totals companies reported as associated with Sympazan. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Katherine Labiner Austin, TX Epilepsy $11,055.68
Steven Wolf New York, NY Neurology (Psychiatry & Neurology) $9,913.89
Ajay Gupta Cleveland, OH Neurology With Special Qualifications In Child Neurology $9,000.00
Alison Dolce Irving, TX Neurology With Special Qualifications In Child Neurology $5,788.65
Andrea Lowden Irving, TX Neurology With Special Qualifications In Child Neurology $5,788.65
Syndi Seinfeld Hollywood, FL Neurology With Special Qualifications In Child Neurology $5,482.95
Marcos Valdez Corpus Christi, TX Neurology With Special Qualifications In Child Neurology $4,513.83
Marytery Fajardo Miami, FL Neurology With Special Qualifications In Child Neurology $4,088.95
Juan Santos Corpus Christi, TX Neurology (Psychiatry & Neurology) $4,027.28
Fawzia Zawahir Brooklyn, NY Family Medicine $3,369.00

Prescribed Sympazan?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.